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Abstract
Purpose Somatostatin receptor expression has been dem-
onstrated on a number of plasma cell lines. Therefore, we
questioned whether somatostatin receptor scintigraphy
(SRS) can be used to demonstrate in vivo multiple
myeloma (MM) activity.
Methods SRS was performed in newly diagnosed (n=9) or
relapsing (n=18) MM patients or in patients with localized
plasmacytoma (n=2). The results were compared with
radiographic findings.
Results A positive SRS was demonstrated in 44% of the
newly diagnosed patients, in 83% of the relapsed patients
and in both patients with plasmacytoma. The SRS findings
corresponded with radiographic abnormalities in 40% of the
patients. However, in relapsed patients 60% demonstrated
increased SRS uptake in areas without new radiographic
abnormalities. The positive SRS corresponded with histo-
logically proven disease activity and responded upon
treatment. Moreover, immunohistochemical staining of
MM material demonstrated concordant somatostatin recep-
tor sst3 staining in five of six patients.
Conclusion These results demonstrate that SRS is a
valuable tool to detect disease activity, especially in
relapsing MM patients.
Keywords Somatostatinreceptorscintigraphy.Multiple
myeloma.Diseaseactivity
Introduction
Multiple myeloma (MM) is a clonal B-cell disorder
characterized by a monoclonal plasma cell population in
bone marrow, with bone pain as a result of skeleton
abnormalities, hypercalcaemia and kidney dysfunction [1].
In a minority of the patients the disorder is localized and
presents as a solitary plasmacytoma. In 60–70% of the
patients skeletal abnormalities are identified by X-ray
A. Agool: R. H. J. A. Slart: R. A. J. O. Dierckx
Department of Nuclear Medicine and Molecular Imaging,
University of Groningen
and University Medical Centre Groningen,
Groningen, The Netherlands
A. Agool
e-mail: a.agool@ngmb.umcg.nl
P. M. Kluin: L. Visser
Department of Pathology, University of Groningen
and University Medical Centre Groningen,
Groningen, The Netherlands
P. L. Jager
Department of Nuclear Medicine,
Hamilton Health Sciences/McMaster University,
Hamilton, ON, Canada
E. Vellenga
Department of Internal Medicine, Division of Hematology,
University of Groningen and University Medical
Centre Groningen,
Groningen, The Netherlands
A. Agool
Department of Nuclear Medicine, Twenteborg Hospital,
Zilvermeeuw 1,
7609 PP Almelo, The Netherlands
E. Vellenga (*)
Department of Hematology,
University Medical Centre Groningen,
Hanzeplein 1,
9700 RB Groningen, The Netherlands
e-mail: e.vellenga@int.umcg.nl
Eur J Nucl Med Mol Imaging (2010) 37:124–130
DOI 10.1007/s00259-009-1199-5examination and are characterized by typical osteolytic
defects [1]. Following treatment with chemotherapy or
radiotherapy the osteolytic defects persist and no clear
distinction can be made whether vital tumour cells are
present in these lesions. Also in relapsing disease the X-ray
examination has a limited value unless progressive defects
are observed. Therefore, it would be attractive to have
scanning methods that identify the metabolic activity of the
malignant plasma cells. Previous studies have shown that
FDG PET might identify the metabolic activity of the
malignant plasma cells. Several studies have demonstrated
that in a high percentage of newly diagnosed MM patients
osteolytic lesions are FDG PET positive due to their higher
metabolic activity [2, 3]. An alternative approach would be
the use of tracers that identify tumour-specific receptors. In
vitro studies with plasma cell lines have shown that the
somatostatin receptor is expressed on malignant plasma
cells. It was shown that all MM cell lines express functional
somatostatin receptors (sst) and that the subtypes sst2, sst3
and predominantly sst5 were present [4]. It is therefore
conceivable that somatostatin receptor scintigraphy (SRS)
using
111mIn-pentetreotide may be a good alternative to
study the presence of the malignant plasma cells [5]. So far
SRS has been used for the detection of neuroendocrine
tumours and aggressive malignant lymphoma especially to
define the extent of the disease [6, 7]. Based on these
findings we performed SRS in patients with MM or
plasmacytoma to determine whether SRS can be used as
an alternative method to detect disease activity in malignant
plasma cell disorders.
Materials and methods
Patients
A total of 29 patients were prospectively included in this
study (Table 1). The patient group consisted of 22 men and
7 women with a median age of 59 years (range: 40–
85 years). MM or plasmacytoma was based on the presence
of a monoclonal plasma cell population in the bone marrow
biopsy, the presence of a monoclonal Ig protein or free light
chains (FLC) in serum according to internationally defined
guidelines [1].
In all patients total whole-body radiography was per-
formed. In a selected number of patients an additional CT
scan or MRI scan was performed based on clinical
symptoms. Patients were treated according to ongoing trials
for MM patients younger than 65 years or with melphalan/
prednisolone [8–10]. Patients (< 65 years) were treated
upfront with three cycles of VAD (vincristine, doxorubicin,
dexamethasone) or TAD (thalidomide, doxorubicin, dexa-
methasone). This was followed by peripheral blood stem
collection following high-dose cyclophosphamide plus
granulocyte colony stimulation factor. Finally autologous
stem cell transplantation was performed with high-dose
melphalan and re-infusion of autologous stem cells. The
protocol was approved by the Medical Ethics Committee
Groningen, The Netherlands and informed consent was
obtained from all patients.
Immunohistochemistry
Bone marrow biopsy or material of extra-osseous localiza-
tion of MM patients was used for these investigations. In
two cases the localization was based on a positive SRS.
Table 1 Patient characteristics at presentation or at relapse
Patient
No.
Age
(years)
Sex Type of
underlying
disorder
Paraprotein SRS
1 63 F MM IgA-κ +
2 58 F MM IgG-κ –
3 54 M MM IgG-λ –
4 57 M MM FLC-κ +
5 62 M MM IgA-κ +
6 53 M MM IgG-κ –
7 52 M MM IgG-κ +
8 51 M MM IgG-λ –
9 62 M MM IgG-κ –
10 60 M Plasmacytoma IgA-λ +
11 40 M Plasmacytoma IgG-κ +
12 85 M MM-R IgA-κ +
13 56 F MM-R IgG-κ +
14 61 M MM-R IgG-κ –
15 64 M MM-R IgG-κ +
16 55 M MM-R FLC-κ +
17 46 M MM-R FLC-κ +
18 48 M MM-R FLC-λ +
19 70 M MM-R FLC-κ +
20 60 M MM-R IgG-κ +
21 63 M MM-R IgG-κ +
22 63 M MM-R IgG-κ +
23 59 M MM-R IgG-κ +
24 67 F MM-R IgG-λ –
25 48 M MM-R FLC-κ +
26 73 M MM-R NS –
27 65 F MM-R FLC-κ +
28 60 F MM-R FLC-λ +
29 64 F MM-R NS +
NS non-secretor, FLC free light chain in serum, MM multiple
myeloma, R relapse, SRS somatostatin receptor scintigraphy with a
positive (+) or negative (-) scan
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aldehyde (12–24 h) and decalcified using a mixture of 10%
acetic acid and 4% formaldehyde (24–48 h). After standard
tissue processing biopsies were embedded in paraffin wax.
Four-micrometer sections were cut and floated onto 3-
aminopropylethoxysilane (APES)-coated slides. After dew-
axing slides were microwaved in 10 mmol/l citrate buffer,
pH 6.0, for 15 min at 750 W, allowed to cool to room
temperature and washed three times in triethanolamine-
buffered saline. The slides were processed using a
Techmate Horizon (Dako, Carpinteria, CA, USA) slide
processor. Affinity purified polyclonal rabbit antisera
specifically directed against sst2 (NB100-74537), sst3
(NLS2622) and sst5 (NLS2639) (1 µg/ml, Novus Bio-
logicals, Littleton, CO, USA) were incubated for 1 h
and binding was visualized using a streptavidin-biotin
complex reagent (StrepABComplex/HRP Duet, Dako,
Carpinteria, CA, USA). Chromogenic substrate was
3,3′-diaminobenzidine. Slides were counterstained with
haematoxylin. Positive control of immunostaining was
assessed by immunohistochemistry of normal pancreatic
islets. However, on bone marrow trephines, satisfactory
results were only obtained for the sst3 staining and not
for sst2 and sst5. In general, if possible all myeloma
Table 2 Somatostatin receptor scintigraphy in multiple myeloma patients receiving upfront treatment or at relapse
Patient No. SRS Corresponding defects on
whole-body radiography
(Y/N)
Whole-body radiography
Scan pos. No. of lesions Uptake ratio No. lesions
> 1cm
No. lesions
< 1cm
New lytic lesions at
relapse > 1cm
1 + 1 1.5 Y 4 Y
2 – 0 –– 3Y
3 – 0 –– 0N
4+ 1 2 Y 3Y
5 + 1 2.3 N
a 0N
6 – 0 –– 1N
7 + 2 2.5 Y 0 Y
8 – 0 – 0Y
9 – 0 –– 0N
10 + 1 2 N
a 0N
11 + 1 1.5 Y 0 N
12 + 11 2 (1.5–2.5) N 0 N 0
13 + 2 2 (1.8–2.2) N 0 N 0
14 – 0 –– 4Y 1
15 + 1 2.5 Y 3 N 1
16 + 1 1.5 Y 6 Y 1
17 + 1 2 Y 4 Y 1
18 + 3 3 (2.8–3.2) Y
b 3Y 3
19 + Diffuse n.a. N 0 Y 0
20 + 12 2 (1.5–2.5) N 3 N 0
21 + 1 1.3 Y
a 2Y 1
22 + 1 2 Y 5 Y 1
23 + 3 2 (1.7–2.2) N 0 N 0
24 – 0 –– 0Y 0
25 + 3 2 N 5 N 0
26 – 0 –– 0N 0
27 + 1 2 N 5 Y 0
28 + 3 3 (2.6–3.3) N
b 3Y 2
29 + 1 1.4 N
a 0Y 0
Lytic lesions larger than 1 cm; osteolytic defects present (Y) or absent (N)
n.a. not available
aNo abnormalities on whole-body radiography, but defects on MRI or CT scan
bExtra-osseous localization
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of myeloma cells was reported using the following
system: 0: no or extremely weak, +: moderate and ++:
strong.
Octreotide scintigraphy
Whole-body scan SRS was performed 24 h after intra-
venous injection of 200 MBq
111In-pentetreotide. A
Multispect 2 Siemens double-headed gamma camera
(Siemens Medical Systems, USA) was used with a matrix
of 256×256 and equipped with medium-energy collima-
tor. Patients were positioned supine on the imaging table;
subsequently six views were obtained: anterior and
posterior of head/neck/thorax, abdomen and the thighs,
10 min/view. The SRS scan and skeletal X-ray were
performed within 7 days.
SRS were separately examined by two experienced
nuclear physicians using visual examination with special
attention to the skeleton. Any focal tracer accumulation
exceeding normal regional tracer uptake levels was rated as
pathological. Subsequently, regions of interest (ROIs) were
visually placed over the area with abnormal uptake and
tracer uptake was quantified by comparing the average
counts per pixel of the focus in comparison with normal
background bone activity assessed from a usually symmet-
rically placed contralateral background ROI. A simple
scoring system was developed to grade the uptake in the
pathological sites. Uptake was recognized as ‘slightly
elevated’ if the uptake ratio exceeded 1.5 in the lesion, as
‘moderate’ when the uptake ratio was between 1.5 and 2,
and as ‘high’ when over 2. Non-focal intestinal uptake
changing over time was considered to be physiological
background activity. All scintigraphic results were com-
pared with radiographic findings.
Results
A total of 27 patients with MM and 2 patients with
plasmacytoma were studied. Patient characteristics are
presented in Table 1. Of the 27 patients with MM, 9
patients had newly diagnosed and 18 patients had relapsing
disease. MM showed production of IgG-κ (n=12), IgG-λ
type (n=3) and IgA-λ or IgA-κ (n=4) types. In eight
patients monoclonal FLCs were demonstrated in the serum.
Whole-body radiography demonstrated abnormalities in
14 of the 29 patients.
The type of treatment was dependent on age and whether
the patient presented with newly diagnosed or relapsing
disease. The newly diagnosed patients (age: 51–63 years)
were treated with intensive chemotherapy and autologous
stem cell transplantation [9, 10]. Relapsing patients (age:
46– 85 years) were treated with variable combinations of
dexamethasone, cyclophosphamide, thalidomide or borte-
zomib. The two patients with solitary plasmacytoma (age:
40 and 60 years) were treated with radiotherapy with and
without intensive chemotherapy (Table 2).
b
a
Fig. 1 Elevated SRS uptake in
the distal right femur matching
with the osteolytic lesion on
skeletal X-ray (both white
arrows). There is no SRS uptake
in the osteolytic lesion of the
proximal right femur on skeletal
X-ray (small black arrow)
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In all patients SRS was performed. In five patients a second
scan was obtained after 3–5 months of treatment. The
number of affected areas on the SRS varied between 1 and
12 per patient. The median uptake ratio was 2.0 (range:
1.3–3.5). Based on a comparison with the abnormalities
seen by whole-body radiography, we defined that SRS was
only positive in lesions with a diameter of more than 1 cm.
In four of the nine [44%, 95% confidence interval (CI):
0.12–0.77] newly diagnosed MM patients the SRS was
positive, in the other five patients the SRS was normal
(Fig. 1). Two of these five patients had distinct abnormal-
ities by whole-body radiography. In both patients with
solitary plasmacytoma, a positive SRS was obtained of the
affected area which was confirmed by X-ray examination
and CT scanning.
SRS was studied in 18 MM patients with relapsing
disease. A positive SRS was shown in 15 of 18 (83%, 95%
CI: 0.66–1) of these patients. In 6 of the 15 (40%, 95%
CI: 0.15–0.60) evaluable patients the increase in SRS
corresponded with new abnormalities on the whole-body
radiography, whereas in the other 9 patients (60%, 95%
CI: 0.35–0.85) enhanced SRS activity was not accompanied
by new abnormalities on the whole-body radiography.
To verify that the increased octreotide uptake was related
to disease activity, biopsies were performed of the affected
areas (pelvis, clavicula) in four patients (1, 10, 11 and 18).
In all four cases histologically proven MM activity was
present.
To study the effect of treatment, follow-up scans were
performed in five cases. Scans performed after 3–4 months
of treatment demonstrated a complete disappearance of
lesions in three patients and a decrease in two. These
changes corresponded with reduced disease activity includ-
ing declining paraprotein or FLC levels (Fig. 2, Table 3).
Finally the somatostatin receptor expression sst3 was
studied on biopsy material of patients with MM. It included
bone marrow biopsy material and one extra-osseous
manifestation of MM. In total six patients were studied:
four patients with a positive SRS scan and two patients with
a negative scan. Three of four patients with a positive SRS
Table 3 Follow-up results of SRS scan after 3 months of treatment
Patient No. Type of paraprotein Paraprotein level SRS Treatment
Upfront Follow-up Upfront Follow-up
a
1 FLC-κ 204 – 2+ – VAD
11 IgG-κ 37 – 4+ – VAD
12 IgG-κ 17 – 3+ – Thalid/dexa
18 FLC-λ 885 – 68 + +/- Thalid/dexa
20 FLC-κ 382 – 40 + +/- Thalid/dexa
aFollow-up scan was performed 3–4 months after start of treatment with thalidomide (thalid), dexamethasone (dexa) or vincristine, Adriamycin
and dexamethasone (VAD). Free light chain (FLC) serum level; normal range: FLC-λ 4.4–32 mg/ml; FLC-κ 2.3–20 mg/ml
b a c
Fig. 2 Somatostatin receptor scintigraphy of the pelvis posterior view
in a patient with multiple myeloma in the left iliac bone, with elevated
SRS uptake before treatment (small black arrow)( a) and normaliza-
tion after treatment (b). The X-ray shows a persistent matching
osteolytic bone lesion (small black arrow)( c)
128 Eur J Nucl Med Mol Imaging (2010) 37:124–130showed positively stained MM cells, two of them showing
strongly positive cells. One patient with a positive scan
showed few strongly positive cells whereas no immunos-
taining was observed on the majority of the MM cells. One
patient with a negative scan showed entirely negative
tumour cells, and the other showed occasionally positive
cells (Table 4, Fig. 3). Although the series of patients is
very small, we also looked for a possible relationship
between the SRS results and tumour load in the biopsies,
since negative SRS results might have been caused by a
less prominent infiltrate. No such correlation was found
(data not shown).
Discussion
Several methods are available to demonstrate disease
activity and bone lesions in patients with MM. Whole-
body radiography has been most frequently used so far and
demonstrates the characteristic osteolytic lesions in 60–70%
of the patients [1]. By using MRI scanning a further
increase in skeletal abnormalities can be demonstrated.
Recently, alternative techniques have been developed that
make use of an increased metabolic activity of the
malignant plasma cells. FDG PET as well as
99mTc-
sestamibi scanning have shown that in 80–90% of the
patients abnormal areas of increased uptake are present
which are frequently associated with abnormal lesions on
whole-body radiography [2, 3, 11, 12]. In addition, there is
evidence that the increased uptake of the
99mTc-sestamibi
correlates with other measurable parameters of disease
activity including C-reactive protein, lactate dehydrogenase
and β2-microglobulin [11, 12].
Previous studies have shown that MM cell lines express
functional receptors for sst2, sst3 and in particular sst5 and
that in vitro growth of myeloma cells can be inhibited by
somatostatin and its analogue octreotide [4]. Although the
role of these receptors remains enigmatic in lymphoid cells,
these findings provided us a rationale to study SRS in the
clinical management of myeloma. It has been demonstrated
that the currently used radiopharmaceuticals for somato-
statin receptor targeting do not bind with high affinity to all
presently known somatostatin receptor subtypes. They bind
with very high affinity to sst2 and with somewhat lower
affinity to sst3 and sst5 but not to sst1 and sst4.
Table 4 Immunohistochemistry for somatostatin receptor subtype
sstr3
Patient No. SRS scan sstr3
1 Positive Heterogeneous
3 Negative Heterogeneous
6 Negative Negative
11 Positive Moderate
23 Positive Strong
28 Positive Strong
Expression of somatostatin receptor subtype sst3 was studied on bone
marrow material of multiple myeloma patients or extra-osseous
manifestation of multiple myeloma. Patient No. reflects the number
in Table 1; sst3 staining was quantified semi-quantitatively as
described in the “Materials and methods” section. Patient 1 showed
mainly negative tumour cells, but within the tumour individual,
strongly positive lymphoid cells
Fig. 3 a Normal pancreatic tissueshowing positive islets and negative exocrinetissue (original magnification ×200). b Patient 1 with mainly negative
but incidentally strongly positive tumour cells (see also the insert; original magnification ×400). c Patient 23 with strongly positive tumour cells
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alternative method to visualize in vivo MM activity.
Although the number of patients with de novo disease is
limited, the data in patients with relapsing disease suggest
that SRS is more sensitive than other methods. The SRS
was abnormal in 82% of the patients, whereas conven-
tional whole-body radiography revealed new lesions in
only 33% of the same patients. Histological analysis in six
patients proved that the abnormal lesions as revealed by
SRS were tumour related. Moreover, in most patients
SRS-positive areas stained at least for the somatostatin
receptor subtype sst3. Unfortunately, immunohistochemis-
try for sst2 and sst5 which was most widely expressed in
myeloma cell lines was unsatisfactory [4].
Patients responsive to treatment demonstrated total or
partialnormalizationoftheabnormaluptakeafter3–4months
of treatment,whichcorrelatedwith a decline of other disease-
related parameters. A remarkable finding was the fact that a
positive SRS was more frequently noticed in relapsing MM
patients than in upfront patients. It is unlikely that the
difference is linked to the number of patients studied. Since
we identified several MM cases with histologically massive,
diffuse infiltrates that were mainly negative in immunohisto-
chemistry, it is also unlikely that the differences in detection
rate by SRS were caused by differences in growth pattern. It
is more conceivable that an enhanced somatostatin receptor
expression is shown in a more advanced state of the disease.
This would be in line with the strong positive somatostatin
receptor expression on MM cell lines which reflects also a
more aggressive type of MM. Also in two patients with
plasmacytoma a localized abnormal SRS could be shown.
Although the number of patients studied is limited, these
findings suggest that SRS might be a good alternative that
verifies whether a localized disease is present. However, the
skeletal abnormalities require a certain diameter. In our hands
defects ≥1 cm were in general noticed by SRS. Smaller
lesions were in general not shown on SRS. Improved
localization of the abnormal SRS might further be obtained
by combining it with the SPECT/CT scan. Also
99mTc-
labelled somatostatin is a preferable diagnostic radionuclide
for higher scan quality because of favourable decay
properties (6 h half-life, gamma radiation of 140 KeV) that
allow administration of a large dose, to yield high-resolution
images, as well as lower cost and easy on-site availability
by the
99Mo/
99mTc generator in the clinic. PET labelled
somatostatin analogues like
68Ga-DOTATOC or
68Ga-
DOTANOC are also an interesting option, due to the higher
resolution of PET camera systems.
In summary, the results demonstrate that SRS is a
valuable tool to detect tumour activity in MM especially
in patients with relapsing disease.
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